Sequana Medical announces H1 2022 results and provides business update

  • alfapump® – strong interim data / on track to report primary endpoint data of North American pivotal POSEIDON study in Q4 2022
  • DSR® – clinical evidence of disease-modifying heart failure drug therapy / preparations ongoing to start US phase 1b/2a MOJAVE study in H1 2023
  • Total liquidity position of €23.8 million and cash runway into Q3 2023

Conference call with live webcast presentation today at 03:00 pm CET / 09:00 am ET

Ghent, Belgium – 8 September 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.

Read more…